Related Experiment Videos
P-selectin as a candidate target in atherosclerosis.
Tom J M Molenaar1, Jaap Twisk, Sonja A M de Haas
1Division of Biopharmaceutics, Leiden/Amsterdam Center for Drug Research, Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands.
Biochemical Pharmacology
|September 2, 2003
Summary
P-selectin plays a key role in atherosclerosis development. Researchers identified novel peptide antagonists for P-selectin, offering potential therapeutic strategies against this cardiovascular disease.
Area of Science:
- Cardiovascular Biology
- Immunology
- Molecular Biology
Background:
- P-selectin is crucial in early atherogenesis, mediating leukocyte adhesion to injured endothelium.
- Validating P-selectin as a therapeutic target requires understanding its expression and identifying specific inhibitors.
Purpose of the Study:
- To quantify P-selectin mRNA expression in atherosclerosis-prone mice.
- To discover novel peptide-based lead structures that antagonize P-selectin function.
Main Methods:
- Real-time PCR was used to measure P-selectin mRNA levels in apoE-deficient mice.
- Phage display technology was employed to isolate P-selectin-specific phage clones and their peptide antagonists.
Main Results:
- P-selectin mRNA expression in apoE-/- mice increased significantly with age, correlating with atherosclerotic lesion progression.
- A highly P-selectin-specific phage clone was isolated, and its synthetic peptide-equivalent demonstrated P-selectin antagonism.
Conclusions:
- P-selectin expression is closely linked to both early and advanced stages of atherosclerotic lesion development.
- Developed P-selectin ligands represent promising tools for targeting or inhibiting P-selectin in the context of arterial inflammation.